Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Compound 545
2. Exypaque
3. Iohexol 350
4. Nycodenz
5. Omnipaque
1. 66108-95-0
2. Omnipaque
3. Nycodenz
4. Exypaque
5. Iohexolum
6. Omnipaque 240
7. Omnipaque 70
8. Omnipaque 140
9. Omnipaque 180
10. Omnipaque 210
11. Omnipaque 300
12. Omnipaque 350
13. Win 39424
14. Oraltag
15. Win-39424
16. Chebi:31709
17. N,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
18. 5-[acetyl(2,3-dihydroxypropyl)amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
19. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
20. N1,n3-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
21. 4419t9mx03
22. Nsc-759636
23. Ncgc00166000-01
24. Dsstox_cid_3157
25. 5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
26. Dsstox_rid_76895
27. Dsstox_gsid_23157
28. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
29. Histodenz
30. Iohexolum [inn-latin]
31. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
32. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
33. 5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
34. Smr000857075
35. Einecs 266-164-2
36. Brn 2406632
37. Unii-4419t9mx03
38. Omnipaque (tn)
39. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
40. N,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide
41. Prestwick_802
42. Cas-66108-95-0
43. Iohexol [usan:usp:inn:ban:jan]
44. Iohexol [vandf]
45. Iohexol [usan]
46. Iohexol [inn]
47. Iohexol [jan]
48. Iohexol [mi]
49. Iohexol [mart.]
50. Prestwick0_000512
51. Prestwick1_000512
52. Prestwick2_000512
53. Prestwick3_000512
54. Iohexol [usp-rs]
55. Iohexol [who-dd]
56. Iohexol [who-ip]
57. Nycodenz;omnipaque;exypaque
58. Ec 266-164-2
59. Iohexol, Analytical Standard
60. Schembl26501
61. Bspbio_000463
62. Mls001332585
63. Mls001332586
64. Mls002153854
65. Iohexol (jp17/usp/inn)
66. Iohexol [ep Impurity]
67. Iohexol [orange Book]
68. Spbio_002384
69. Iohexol [ep Monograph]
70. Bpbio1_000511
71. Iohexol [usp Monograph]
72. Chembl1200455
73. Dtxsid6023157
74. Bcbcmap01_000051
75. Iohexolum [who-ip Latin]
76. Hms1569h05
77. Hms2096h05
78. Hms2235d07
79. Hms3369o04
80. Hms3713h05
81. Albb-028959
82. Amy21804
83. Bcp31800
84. Hy-b0594
85. Tox21_112286
86. Bdbm50247977
87. Iohexol (mixture Of Isomers)
88. Mfcd00077732
89. S4531
90. Akos015895399
91. Tox21_112286_1
92. Ac-1934
93. Ccg-220512
94. Db01362
95. Nsc 759636
96. Smp1_000152
97. Ncgc00166000-02
98. Ncgc00166000-04
99. As-12699
100. Ft-0627276
101. I0903
102. D01817
103. D91214
104. Histodenz(tm), Nonionic Density Gradient Medium
105. 108i950
106. A835339
107. Q410683
108. Sr-01000838892
109. Sr-01000838892-2
110. Iohexol, European Pharmacopoeia (ep) Reference Standard
111. Iohexol, United States Pharmacopeia (usp) Reference Standard
112. 5-(n-dhp-acetamido)-2,4,6-triiodo-n,n'-b Is-dhp-isophthalami
113. Iohexol, Pharmaceutical Secondary Standard; Certified Reference Material
114. Iohexol For Peak Identification, European Pharmacopoeia (ep) Reference Standard
115. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo
116. 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
117. 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
118. N1,n3-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
119. N1,n3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
| Molecular Weight | 821.1 g/mol |
|---|---|
| Molecular Formula | C19H26I3N3O9 |
| XLogP3 | -3 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 12 |
| Exact Mass | 820.8803 g/mol |
| Monoisotopic Mass | 820.8803 g/mol |
| Topological Polar Surface Area | 200 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 653 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 3 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Omnipaque 180 |
| PubMed Health | Iohexol (Injection) |
| Drug Classes | Radiological Non-Ionic Contrast Media |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 38.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 2 of 4 | |
|---|---|
| Drug Name | Omnipaque 240 |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 51.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 3 of 4 | |
|---|---|
| Drug Name | Omnipaque 180 |
| PubMed Health | Iohexol (Injection) |
| Drug Classes | Radiological Non-Ionic Contrast Media |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 38.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 4 of 4 | |
|---|---|
| Drug Name | Omnipaque 240 |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 51.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
V08AB02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
V - Various
V08 - Contrast media
V08A - X-ray contrast media, iodinated
V08AB - Watersoluble, nephrotropic, low osmolar x-ray contrast media
V08AB02 - Iohexol
Absorption
Small amounts are absorbed through the bladder via intravesical instillation. Following intrauterine instillation, the majority of the medium within the uterine cavity is discharged into the vagina immediately upon termination of procedure. However, any medium retained in the uterine or peritoneal cavity is absorbed systemically within 60 minutes. May not be absorbed for up to 24 hours if tubes are obstructed and dilated.
Route of Elimination
Iohexol is absorbed from cerebrospinal fluid (CSF) into the bloodstream and is eliminated by renal excretion. No significant metabolism, deiodination, or biotransformation occurs.
Volume of Distribution
350-849 mL/kg
Clearance
109 mL/min [Adult patients receiving 16-18 ml of iohexol (180 mgI/mL) by lumbar intrathecal injection]
Intrathecal half-life is 3.4 hours (mean). Intravascular is approximately 2 hours (with normal renal function).
Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Topical
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Iohexol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Iohexol, including repackagers and relabelers. The FDA regulates Iohexol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Iohexol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Iohexol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Iohexol supplier is an individual or a company that provides Iohexol active pharmaceutical ingredient (API) or Iohexol finished formulations upon request. The Iohexol suppliers may include Iohexol API manufacturers, exporters, distributors and traders.
click here to find a list of Iohexol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Iohexol DMF (Drug Master File) is a document detailing the whole manufacturing process of Iohexol active pharmaceutical ingredient (API) in detail. Different forms of Iohexol DMFs exist exist since differing nations have different regulations, such as Iohexol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Iohexol DMF submitted to regulatory agencies in the US is known as a USDMF. Iohexol USDMF includes data on Iohexol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Iohexol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Iohexol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Iohexol Drug Master File in Japan (Iohexol JDMF) empowers Iohexol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Iohexol JDMF during the approval evaluation for pharmaceutical products. At the time of Iohexol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Iohexol suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Iohexol Drug Master File in Korea (Iohexol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Iohexol. The MFDS reviews the Iohexol KDMF as part of the drug registration process and uses the information provided in the Iohexol KDMF to evaluate the safety and efficacy of the drug.
After submitting a Iohexol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Iohexol API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Iohexol suppliers with KDMF on PharmaCompass.
A Iohexol CEP of the European Pharmacopoeia monograph is often referred to as a Iohexol Certificate of Suitability (COS). The purpose of a Iohexol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Iohexol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Iohexol to their clients by showing that a Iohexol CEP has been issued for it. The manufacturer submits a Iohexol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Iohexol CEP holder for the record. Additionally, the data presented in the Iohexol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Iohexol DMF.
A Iohexol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Iohexol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Iohexol suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Iohexol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Iohexol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Iohexol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Iohexol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Iohexol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Iohexol suppliers with NDC on PharmaCompass.
Iohexol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Iohexol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Iohexol GMP manufacturer or Iohexol GMP API supplier for your needs.
A Iohexol CoA (Certificate of Analysis) is a formal document that attests to Iohexol's compliance with Iohexol specifications and serves as a tool for batch-level quality control.
Iohexol CoA mostly includes findings from lab analyses of a specific batch. For each Iohexol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Iohexol may be tested according to a variety of international standards, such as European Pharmacopoeia (Iohexol EP), Iohexol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Iohexol USP).
LOOKING FOR A SUPPLIER?
